NCT01283698

Clinical Trial to Investigate Efficacy of LAS41004 in Psoriasis

An Investigator-blind, Controlled Study to Assess the Efficacy of Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Active Control in a Psoriasis-Plaque-Test

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Almirall, S.A. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to intra-individually compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT)

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Experimental: LAS 41004 dosage 1	dosage 1, once daily
DRUG	Experimental: LAS 41004 dosage 2	LAS 41004 dosage 2, once daily
DRUG	Experimental: LAS 41004 dosage 3	dosage 3, once daily
DRUG	Placebo Comparator: placebo	once daily
DRUG	Reference	Active Comparator,once daily

Timeline

• Start date: 2011-01-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2011-01-26
• Last updated: 2015-05-29

Locations

1 site across 1 country: Germany